Physician profile
Philip Downs
NPI 1851711188
$1,942.28
in general payments reported to CMS, 2019-2025
25 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $14.04 · 2023: $1,270 · 2024: $658.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,839 · Education: $89.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,839.24 |
| Education | $89.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myriad Genetic Laboratories, INC. | $275.98 | 2023-2024 | Prolaris |
| Coloplast Corp | $263.06 | 2023-2024 | Speedicath |
| Merck Sharp & Dohme LLC | $213.46 | 2023-2024 | Keytruda, Lynparza |
| Pfizer INC. | $171.85 | 2023 | |
| Astellas Pharma US INC | $123.70 | 2023-2024 | Xtandi, Myrbetriq |
| Axonics, INC. | $104.89 | 2023-2024 | Bulkamid, Axonics |
| Bayer Healthcare Pharmaceuticals INC. | $79.83 | 2023-2024 | |
| Tolmar, INC. | $71.29 | 2023-2024 | |
| 180 Medical, INC. | $69.98 | 2023-2024 | Gentlecath Glide, Gentlecath |
| Blue Earth Diagnostics | $68.90 | 2024 | |
| Endo Pharmaceuticals INC. | $64.96 | 2023 | Xiaflex |
| Janssen Biotech, INC. | $63.16 | 2023-2024 | Erleada |
| Urogen Pharma, INC. | $56.27 | 2023-2024 | Jelmyto |
| Sumitomo Pharma America, INC. | $54.62 | 2023-2024 | Gemtesa, Orgovyx |
| Halozyme INC | $52.12 | 2023 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Immunitybio, INC. | $39.98 | 2024 | |
| Abbvie INC. | $36.26 | 2023-2024 | |
| Lundbeck LLC | $22.47 | 2023 | Vyepti |
| Dendreon Pharmaceuticals LLC | $18.22 | 2023 | Provenge |
| Teleflex LLC | $17.10 | 2023 | Urolift |
| Ferring Pharmaceuticals INC. | $16.42 | 2024 | Adstiladrin |
| Astrazeneca Pharmaceuticals Lp | $16.09 | 2024 | Lynparza |
| Antares Pharma, INC. | $14.13 | 2024 | Xyosted |
| Djo, LLC | $14.04 | 2022 | |
| Ambu INC. | $13.50 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Philip Downs listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.